Common gene rearrangements in prostate cancer.
暂无分享,去创建一个
[1] J. Cuzick,et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate , 2008, Oncogene.
[2] Arul M Chinnaiyan,et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. , 2006, Cancer research.
[3] J. Damber,et al. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. , 2007, Oncology reports.
[4] Eric S. Lander,et al. The genomic complexity of primary human prostate cancer , 2010, Nature.
[5] L. Klotz,et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression , 2007, Cancer biology & therapy.
[6] L. Liotta,et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. , 1998, Journal of the National Cancer Institute.
[7] P. Nelson,et al. A causal role for ERG in neoplastic transformation of prostate epithelium , 2008, Proceedings of the National Academy of Sciences.
[8] Lang Li,et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate , 2004, Cancer.
[9] M. Dowsett,et al. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). , 1994, The Journal of steroid biochemistry and molecular biology.
[10] T. Tammela,et al. TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis , 2008, Clinical Cancer Research.
[11] M. Teitell,et al. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells , 2009, Proceedings of the National Academy of Sciences.
[12] Jie Zhang,et al. Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie Specific Translocations in Cancer , 2009, Cell.
[13] David A Hanauer,et al. Bioinformatics approaches in the study of cancer. , 2007, Current molecular medicine.
[14] P. Scardino,et al. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. , 1991, The Journal of urology.
[15] R. Eeles,et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate , 2007, Oncogene.
[16] S. Dhanasekaran,et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. , 2008, Cancer research.
[17] Arul M Chinnaiyan,et al. Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer , 2006, Laboratory Investigation.
[18] O. Kallioniemi,et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. , 2006, Cancer research.
[19] M. Rubin,et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort , 2009, Modern Pathology.
[20] M. Rubin,et al. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. , 2009, Cancer research.
[21] Yao-Tseng Chen,et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues , 2007, Modern Pathology.
[22] R. Henrique,et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. , 2006, Neoplasia.
[23] R. Shah,et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. , 2008, Cancer research.
[24] A. Chinnaiyan,et al. Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences , 2011, Nature Reviews Genetics.
[25] G. Jenster,et al. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. , 2006, Cancer research.
[26] D. Bostwick,et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. , 1995, Cancer research.
[27] B. Rubin,et al. Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors , 2006, Laboratory Investigation.
[28] Francesca Demichelis,et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma , 2010, Nature Medicine.
[29] Adam S. Kibel,et al. Integrative molecular concept modeling of prostate cancer progression , 2007 .
[30] T. Golub,et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. , 2008, Journal of the National Cancer Institute.
[31] Martin J. Aryee,et al. Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangements , 2010, Nature Genetics.
[32] M. Loda,et al. Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications , 2008, Clinical Cancer Research.
[33] S. Varambally,et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. , 2010, Neoplasia.
[34] S. Varambally,et al. Therapeutic Targeting of SPINK1-Positive Prostate Cancer , 2011, Science Translational Medicine.
[35] R. Tibshirani,et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[36] Lee T. Sam,et al. Transcriptome Sequencing to Detect Gene Fusions in Cancer , 2009, Nature.
[37] Jianfeng Xu,et al. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array , 2006, Genes, chromosomes & cancer.
[38] D. Dearnaley,et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. , 2009, Cancer research.
[39] J. Brooks,et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis , 2007, Modern Pathology.
[40] J. Llovet,et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.
[41] J. Witjes,et al. Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer , 2007, Clinical Cancer Research.
[42] T. Guthrie,et al. Prostate cancer. , 2020, American family physician.
[43] Derek Y. Chiang,et al. EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.
[44] S. Leung,et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers , 2007, Journal of Clinical Pathology.
[45] John T. Wei,et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. , 2008, Cancer cell.
[46] Lei Wang,et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. , 2006, Neoplasia.
[47] B. Haynes,et al. Pharmacology of novel steroidal inhibitors of cytochrome P45017α (17α-hydroxylase/C17–20 lyase) , 1994, The Journal of Steroid Biochemistry and Molecular Biology.
[48] Michael Ittmann,et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.
[49] John F Ward,et al. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. , 2003, The Journal of urology.
[50] D. Grignon,et al. Allelic loss in locally metastatic, multisampled prostate cancer. , 1994, Cancer research.
[51] D. Berney,et al. Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. , 2010, Cancer research.
[52] C. Ahlers,et al. ETS-TMPRSS2 fusion gene products in prostate cancer , 2006, Cancer biology & therapy.
[53] M. Rubin,et al. TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion , 2006, The American journal of surgical pathology.
[54] I. Panagopoulos,et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer , 2006 .
[55] Arul M Chinnaiyan,et al. Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States , 2009, Clinical Cancer Research.
[56] J. Tchinda,et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.
[57] S. Varambally,et al. Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer , 2009, Science.
[58] J Cuzick,et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.
[59] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[60] T. Ratliff. Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report From the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee , 2004 .
[61] M. Bissell. A First-Generation Multiplex Biomarker Analysis of Urine For The Early Detection of Prostate Cancer , 2009 .
[62] R. Shah,et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.
[63] P. Karakiewicz,et al. 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. , 2006, The Journal of urology.
[64] Adam S. Kibel,et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007 .
[65] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[66] A. Evans,et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. , 2006, Neoplasia.
[67] M. Caligiuri,et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] P. Scardino,et al. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. , 2006, The Journal of urology.
[69] Ximing J. Yang,et al. A Working Group Classification of Focal Prostate Atrophy Lesions , 2006, The American journal of surgical pathology.
[70] Debashis Ghosh,et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer , 2007, Modern Pathology.
[71] R. Shah,et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. , 2007, Cancer research.
[72] C. Glass,et al. A Topoisomerase IIß-Mediated dsDNA Break Required for Regulated Transcription , 2006, Science.
[73] O. Ludkovski,et al. Microdeletion and concurrent translocation associated with a complex TMPRSS2:ERG prostate cancer gene fusion , 2007, Genes, chromosomes & cancer.
[74] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[75] A. Kibel. The genomic complexity of primary human prostate cancer: Berger MF, Lawrence MS, Demichelis F, et al (The Broad Inst of Harvard and MIT, Cambridge, MA; Weill Cornell Med College, NY; et al) Nature 470:214-220, 2011 § , 2011 .
[76] S. Dhanasekaran,et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.
[77] Mitch Dowsett,et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] S. Varambally,et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. , 2008, Cancer research.
[79] M. Rubin,et al. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. , 2007, Urology.
[80] M. Gerstein,et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. , 2009, Neoplasia.
[81] S. Luo,et al. Chimeric transcript discovery by paired-end transcriptome sequencing , 2009, Proceedings of the National Academy of Sciences.